SYMPOSIUM INSERM ROAD TO 2030 HORIZON EUROPE

MAIN OBJECTIVES + FUTURE CALLS

Aude RAIMBAULT

EU Policy officer

Cluster Health-Mission

Cancer-IHI partnership

Inserm

aude.raimbault@inserm.fr





INSERM - CELLULE EUROPE

Pôle Relations Européennes (PRE)



Guillaume Fusai Responsable du Pôle Europe



Laurence Garric ERC, EIT Health



Aude Raimbault
Cluster Santé (IHI EDCTP3), mission cancer



Ivone Alves
Communication

er Santé (IHI - EIC Pathfinder

Département des Ressources Humaines (DRH)



Morgane Bureau
Actions Marie S. Curie





Département des Affaires Financières (DAF)



Marion Di Maria Aspects Juridiques et Financiers



Plan d'action pour la mise en œuvre de la stratégie européenne de l'Inserm



MANY INSERM ACTORS CAN HELP YOU FROM YOUR PROJECT IDEA TO YOUR PROJECT SUBMISSION!

If management mandate held by Inserm

CELLULE EUROPE / SIÈGE

- **Identify** the relevant instrument for your project
- Check that your project is in line with the call you have targeted
- Analysis of success factors in winning projects, writing tips
- Rules for participation
- Statistics
- Proof Reading (ERC and MSCA)

cellule.europe@inserm.fr

YOUR REGIONAL DELEGATION

- Identify the relevant instrument for your project
- Check that your project is in line with the call you have targeted
- Assistance with budgetary and legal arrangements
- Financial management of the project if it is selected

INSERM TRANSFERT

- To coordinate projects with several partners
- Dedicated project manager
- Planning, structuring, contribution to drafting
- Administrative organisation
 (partner data collection, meetings, submissic
- Set-up cc



>Complementary actors working closely together





HORIZON EUROPE TRAINING SESSION: KEYS TO SUCCESS

January, 21st-22nd, 2026 - Paris

To help you in non-scientific aspects of your collaborative European project (AMSC- Doctoral Network, Health Cluster)

A good opportunity for:


- Anticipating your submission to a European project;
- Understanding how Horizon Europe works and what it funds;
- Gaining a better understanding of the project submission process;
- Building your project strategy, better structuring your project, improving the drafting of your project, understanding the expectations of the European Commission, etc.

For more information: cellule.europe@inserm.fr





100% of researchers from last year's edition recommend it!



COMMUNICATION AND VISIBILITY INITIATIVES



https://www.calameo.com/books/ 005154450893789c14fb7











Replay – <u>Table ronde</u> – **Devenir expert**évaluateur auprès de la **CE (juin 2024)** Work as an expert | EU **Funding & Tenders** Portal (europa.eu)

Horizon Europe: quels outils pour financer mon projet - Inserm pro





- ➤ Top-down approach and collaborative project in response to a detailed call for proposals
- To carry out a collaborative, multidisciplinary R&D project, with both a societal impact for the benefit of citizens (and patients) and an economic impact on healthcare systems.
- > Involvement as a coordinator or as a partner
- At least 3 legal entities independent from each other and from at least 3 Member states (or Associated countries such as the UK or Switzerland)



3 MAIN EVALUATION CRITERIA

ERIA

After verification of eligibility criteria:

SCIENTIFIC EXCELLENCE

4/5

Clarity and pertinence of the project's objectives, and the extent to which the proposed work is ambitious and goes beyond the state of the art

Credibility of the proposed methodology, in particular the underlying concepts, models, assumptions and inter-disciplinary approaches; sound scientific methodology

Appropriate consideration of the gender dimension in research and innovation content

Quality of open science practices including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.

IMPACT OF THE PROJECT

4/5

To what extent will the project achieve the expected impacts?

Credibility of the pathways to achieved the expected outcomes and impact specified in the work programme, and the likely scale and significance of the contribution due to the project

Suitability and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities

IMPLEMENTATION

4/5

Quality and efficiency of the implementation: quality and effectiveness of the work plan, assessment of risks and appropriatness of the effor assigned to work package and the resources overall

Capacity and role of each participant, and extent to which the consortium as a whole brings together the necessary expertise

Treshold :12/15

Part A Application form
Part B Technical description (45 pages)



Calls 2026-2027 Health Cluster Horizon Europe



In relation with pain and inflammation and musculoskeletal disorders





CLUSTER SANTE - DRAFT 2026-2027

Destination 1 - Staying healthy in a rapidly changing society

			Main objectives	Scope
Addressing disabilities though the life course to support independent living and inclusion	2027 – 1 stage call RIA Opening: 10/02/2027 Deadline for submission: 13/04/2027	5 funded projects 6-8M€/project	Finding the causes of the disease(s) + developing innovative solutions (diagnoses, medicines, treatments, protocols, technologies, digital tools, low-tech solutions) Access to habilitation and rehabilitation services, including psychological rehabilitation and innovative rehabilitation with assistive technologies	Long-term disabilities (physical, mental, intellectual or sensory) aiming at supporting independent living across the life-course from a health perspective Special focus on children with disabilities from the perinatal period, and/or young people with disabilities transitioning to adulthood, and/or older persons





CLUSTER SANTE – DRAFT 2026-2027

Destination 3 - Tackling diseases and reducing disease burden

Prevention and management of chronic non-communicable diseases in children and young people (GACD)

2027 – 1 stage call

RIA

Opening:

10/02/2027

Deadline for

submission:

13/04/2027

3 funded projects

3-4 M€/projet

Implementation research,
exploring strategies, evidencebased program and policy
interventions across prevention,
diagnosis, screening and

management of chronic NCDs

Educational strategies,
vaccination strategies, promotion
of behavioural and lifestyle
changes;

Screening and diagnosis of NCDs (or risk factors) in children and/or young people (in particular use of digital tools);

Any chronic non-communicable condition (or combination of conditions), including mental health disorders, autoimmune conditions, musculoskeletal conditions, neurological disorders and sleep disorders and/or any risk factor (or combination of risk factors)

Chronic NCDs, centred on the critical life stages spanning early childhood to young adulthood (1-24 years of age) living in LMICs, and/or underserved populations in HICs

Proposed intervention(s) for a selected study population(s) based in one or more LMICs, and/or underserved populations experiencing health disparities





CLUSTER SANTE – DRAFT 2026-2027

Destination 5- Developing and using new tools, technologies and digital solutions for a healthy society

Development of predictive biomarkers of disease progression and treatment response by using Al methodologies for chronic noncommunicable diseases

2027 – 2 stage call RIA

6 funded
Opening: projects
10/02/2027 6-8M€/project

(stage 1): 13/04/2027 Deadline for submission (stage 2): 22/09/2027

Deadline for

submission

Clinical development of predictive biomarkers of disease progression and treatment response for chronic NCDs

Adapt and apply of established AI methods rather than developing novel ones from scratch, to deliver novel prognostic and predictive biomarkers of disease progression and treatment response

Establish a biomarker validation platform to assess the clinical utility of the predictive biomarkers identified

Chronic noncommunicable diseases (excluding cancer)





CLUSTER SANTE – DRAFT 2026-2027

Destination 5- Developing and using new tools, technologies and digital solutions for a healthy society

Advancing bioprinting of living cells for regenerative medicine

2027 – 1 stage call RIA

Opening: 3/06/2027

4 funded

projects

10M€/projet

Deadline for submission: 22/09/2027

Develop or improve existing bioprinting equipment

Scale-up the chosen bio-printing technology to a GMP-conform/compliant manufacturing process

Enable the conduct of clinical studies and assess the clinical value of the developed bio-printing technology in first in-human studies

Any therapeutic area: any disease, dysfunction or defect

Priority given to bioprinting approaches that
either target vital
internal organs followed
by surgical grafting or
employ in-situ
approaches depositing
the cell-laden bioink
directly from the
printhead on the defect
target site in the body

Sex differences at the cellular level should be taken into consideration



EUROPEAN INNOVATION COUNCIL



« To make Europe the leader in innovation »

- 1. Finance high risk and radical technological innovation, creating new markets
- 2. « Derisking » to attract private investors
- 3. Accelerate the growth of high potential companies, supporting the best innovators


"The EIC aims at identifying and supporting breakthrough technologies and game-changing innovations with the potential to scale up internationally and become market leaders"





EIC: INNOVATION CHAIN COVERAGE





- Identify and develop radical technological innovations that create markets in the medium to long term.
- Exploratory research excellence inspired by deep tech
- > The objective of the project is the validation of scientific basis in laboratory (TRL 4)
- > The targeted technology (10 years ahead) must be disruptive, high-risk and high-potential.





EIC PATHFINDER HEALTH CHALLENGE IN 2026

Deadline: 28/10/2026



Universities, research organisations, start-ups, etc.



Individual or collaborative project

Single beneficiary (any legal entity excluding large entreprises)

Or a consortium with at least 2 legal entities (public or private) from 2 EU member state or associated countries (core consortium)

or 3 entities from 3 MS or AC

How much?



4 M€ (more if justified)

Scientific part of the proposal: 30 pages



EIC PATHFINDER HEALTH CHALLENGE IN 2026

8 projects will be funded

2/Biotechnology for Healthy Ageing

Identification of biomarkers or proof-of-concept validation of suitable pre-clinical models or bio-pharmaceutical interventions to prevent the emergence or reverts an age-related trait

I of the 3 main objective to achieve:

- An innovative preventative or therapeutic biotechnology-based or pharmaceutical intervention that prevents, delays or reverts the onset of a specific age-related disease => 5 projects max
- A biomarker based tool to enable the responsible deployment of ageing-related interventions, => 3 projects max
- A **New Approach Methodology** (NAM) to go beyond the current state-of-the art to enable the future development of interventions for healthy ageing=> 2 projects max

